Roche Early-Stage Hep C Candidates Show Promise At AASLD
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As Roche aims to maintain a strong position in the hepatitis C market amid the emergence of new treatment mechanisms, the company is seeking to move forward clinical-stage polymerase and protease inhibitors in development.